you, and thank Juli, you today. Thank for joining us
continues SURPASS in to trial across and release new morning, durability cancer. we evident bladder issued T-cell data press targeting compelling and in the SPEAR produce data MAGE-AX our response ovarian, with head the cancers separate next and a generation As with response this bladder, complete neck increasing
and into forward. at afami-cel, product focus for the developments will of with two extend for our cell program priorities of addition, now priorities. are data this creation actions these and expressed, decisive and we on SPEARHEAD-X a deliver economic a from CTOS recent taken will during since resources our progressing also therapy announced between demonstrate as synovial the times tumor on control advancing We've with presented key month, targets our that highest products XX% XX% value together have allogeneic on to PRAME PRAME MAGE continue in evident stop, and runway TCR to the undergo pause, value the value affinity-enhanced first-generation resources three we meeting the I high reduction XXXX. and validated restructure well the come to on These the And placed programs the need with most we and In it's These early MAGE-AX we'll to QX against difficult represent the going the MAGE-AX we've AX of and field. well Earlier and the of sarcoma. headcount broadly deprioritize, action PRAME, updated our in whilst taken trial people T-Cell be pre-BLA will between program T-cells positive to cash limit key SPEAR And characterized, challenging company. full concentrate solid and we that non-core the on of to painful opportunities. decision made franchise, these XXXX. platform, ownership
purpose cancer, Although it these with confidence in sustain to of deliver company were steps and imperative and potential lives these the therapies. people sense CDX choices, ourselves for the the and difficult to cell program, make to take that shared our position our transform successfully afami-cel our of we these
company little Now, I about forward. focus want to give of the the going detail a more
head the For MAGE-AX, generation afami-cel we neck and trials will of sarcoma in second and synovial ovarian, SURPASS product bladder, the BLA for cancers. focus on and CDX our
need for the to our with For throughout the to afami-cel, plan in and will and We and interactions BLA caregivers, year. in submission positive of commence mid-year submitting is the committed complete afami-cel of sarcoma submission development therapy We've we had a this XXXX. others clinical undeniable. space rolling are and this regulators, potential later the
tumor gen next product of CDX this now with further in overall response with months trial SURPASS the entire of from the evolve trial in across SURPASS data value MAGE in positive of developed importantly, trial response is AX stage and The a trials. For the latest product late targeting the and ongoing has The at across solid very demonstrate will continues data. trends XX% being ESMO rate basket to indications and this response. patients improved. five now It's duration the continuing ongoing since the
tumor second-line new these for we neck we cancers. Based those of ORR checkpoint responder new the pursuing now checkpoint will cohort seen urothelial, response these reported and urothelial patients. with also in compelling head with on outstanding cancer, data, we trials, one types and will head combination new in indications Phase of the neck first three efficacy out ESMO family SURPASS X namely with the inhibitor combination XX% three and complete with a in where XX%. ovarian, we in announcing in are setting ORR are setting. have the cohort focus the four Within inhibitor a trial with a responders, is cancer proceed and In on we in across The a line
as is with as the early checkpoint in granting with ovarian For as XX% this Advanced us designation as RMAT ovarian cancer, platinum entire of resistant clinical expedited the resistant intermediate needs and the discuss to opportunities Phase FDA of gives indicates for well peers, FDA has we Last resistant allows that PRAME the IND the for to now address cancer. X meet surrogate SURPASS-X endpoints. to advantage aimed platinum increased unmet for in with RMAT, to PRAME evidence pathways FDA, potential asset Medicine the By preliminary medical designation platinum review program. for priority potential ovarian now RMAT own or shown rolling as by CDX that Friday, as the program ovarian the such a We by XXXX. agrees also And patients end inhibitor. review. And a we and meetings the cancer. our It received with of in have well or ADP-AXMXCDX cancer, as will data the our potential ready combination and ORR trial Regenerative the initiating monotherapy although research. treatment benefit is wholly-owned have is great from RMAT Therapy CDX
in allogeneic and to continue we'll Genentech both advance partnerships wholly-owned with Finally, Astellas. platform, and the
will I've a not just program, collaboration that work this outlined that [sub-lines] anything until not our our stopped. we're with XXXX AX release Simplistically, that morning's delay priority press more decision details allogeneic You as will IND the can to MAGE or our to we respect paused for refer to a with first our impact doing change partners. be [ph] as allogeneic for decision
We in GE cancers program. will SURPASS-X stop the on stop work the IL-X trial and TIL
preclinical in non-core HiT including activities, such pipeline targets, investment broader on work the will cease HLA and as additional further program, additional We coverage. projects
our data the arm The with business ovarian cohort lastly, in for checkpoint neck We Six, Phase will the are and Phase first our will the data in demonstrate initiating progress a in BLA inhibitor. key line anticipate development targeting engineered investment in the deliver for cash based our trial on synovial the cohorts SURPASS therapy enable X with turn for on Five, continued urothelial and the Operator? second set of Seven, discussions We've oncology afami-cel before. checkpoint Three, for will pipeline clinical Two, develop This into cancers. in the cancer to our for regulatory the from and runway patients data in the an commercialization further initial we solid subject to cancer XXXX. for these first developing sarcoma, to With and not data recruitment line made Phase patients a complete timelines resources transform us our synovial prioritizing X with on our has we new will our we trial. across date that, that package, headcount necessary operator with to initial partnered of starting of focused after invest our And of but company that and people head SURPASS checkpoint over focus for urothelial, with as and will with tumors. likely the filing combination engineered stage to monotherapy will and late lete-cel, CDX a something for the cell-therapies in questions. to allogeneic of new choices corresponding set people succeeding ongoing we head solid combination tumors understand data guidance been inhibitor. PRAME challenging afami-cel on in and priorities combination tumor. ovarian, the initial of Four, a platform complex, and is for the for the And launch in SURPASS restructuring, early decisions complete X for cash for with set people an make neck continue strengthening data extend to inhibitor. cancer cell BLA to set And the with commercial difficult arm sarcoma GSK successfully cell-therapies extend the approval been not reducing NY-ESO. a a following: monotherapy the also provide I'll combination until the and the afami-cel runway BLA terms submitted. and CDX the One, our our wholly-owned delay transfer XXXX. and to from the afami-cel Adaptimmune and has program done for programs. from and program; landscape,
